Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03396562
Other study ID # 17-0118
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 29, 2017
Est. completion date March 1, 2028

Study information

Verified date May 2024
Source University of Colorado, Denver
Contact Nicole Tartaglia, MD, MS
Phone (720) 777-8087
Email nicole.tartaglia@childrenscolorado.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is designed to research the natural history of neurodevelopment, health and early hormonal function in infants with XXY/Klinefelter syndrome, XYY, XXX and other sex chromosome variations in an effort to identify early predictors of developmental and health outcomes. The Investigators will also evaluate different developmental screening tools in infants with sex chromosome variations so the investigators can develop recommendations for pediatrician caring for infants and young children with XXY/Klinefelter syndrome, XYY, XXX, and other sex chromosome variations.


Description:

Background: Sex Chromosome Trisomies (SCT) including Klinefelter (XXY), Trisomy X (XXX), and XYY syndromes occur in 1 out of every 500 births and are associated with a broad phenotypic spectrum including increased risk for developmental delays (DD), language/learning disorders, and autism spectrum disorder (ASD). XXY is also associated with testicular failure, XXX increases risk for ovarian failure, and disorders of insulin resistance and other medical problems resulting in increased morbidity and mortality occur in all 3 SCTs. Historically, less than 10% of SCT diagnoses occur in childhood, however the rate of newborns with SCT has markedly increased with new noninvasive prenatal cell-free DNA (cfDNA) screening. SCT natural history research is limited to studies from the 1970's, and the investigators have little knowledge of early predictors of the wide heterogeneity in later outcomes. The high risk for DD in SCT suggests that newborn screening may improve identification for DD and timely initiation of interventions. However, it is not clear whether all SCT infants indeed require intensive developmental assessments and therapies, or if primary care screenings are sufficient to identify those in need. The surge in prenatal SCT diagnoses from cfDNA methods provides an opportunity for longitudinal study of a cohort of infants to explore natural history, and to improve care. Aims: This study aims to: (1) describe and compare the natural history of neurodevelopment, health and early gonadal function in infants with the 3 SCT conditions through a national prospective eXtraordinarY Babies Study in partnership with the Newborn Screening Translational Research Network (NBSTRN), (2) identify early predictors of poor neurodevelopmental and cardiometabolic outcomes, and (3) evaluate the sensitivities of common primary care developmental screening measures to detect DD and ASD in this high-risk population to inform recommendations for an early neurodevelopmental care protocol. Approach: Infants with a prenatal diagnosis of XXY, XYY, or XXX will be followed prospectively every 6-12 months for 2-4 years at 2 eXtraordinarY Kids Clinic sites. Demographics, health history, development, interventions, and social/family history will be collected. Assessments will include: (1) measures of cognitive, language, social, motor, and adaptive function, (2) physical exam, gonadal function labs, cardiometabolic measures, and body composition, and (3) quality of life outcomes. Impact: Prospective study of the natural history of prenatally diagnosed infants with SCT will allow investigation of important questions to inform newborn screening considerations, such as the interplay between early hormonal profiles and developmental outcomes. Results will be immediately relevant for counseling and establishing evidence-based care guidelines for the rapidly increasing rate of SCT diagnoses from cfDNA screening. Results will serve as the basis for ongoing longitudinal studies of health and psychological outcomes of SCTs through the lifespan.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date March 1, 2028
Est. primary completion date March 1, 2028
Accepts healthy volunteers No
Gender All
Age group 6 Weeks to 13 Months
Eligibility Inclusion Criteria: 1. Prenatal diagnosis of sex chromosome aneuploidy (by cfDNA, chorionic villi sampling, and/or amniocentesis) 2. Postnatal confirmatory karyotype of XXY, XYY, XXX, XXYY, XYYY, XXXY, XXXX, XXXXX, XXXXY, XXXYY, XXYYY, XYYYY (including any mosaicism with <80% 46,XX or 46,XY cell line) 3. English or Spanish speaking 4. Age 6 weeks to 12 months 30 days on enrollment Exclusion Criteria: 1. Previous diagnosis of a different genetic or metabolic disorder with neurodevelopmental or endocrine involvement 2. Prematurity less than 34 weeks gestational age 3. Complex congenital malformation not previously associated with sex chromosome aneuploidy 4. History of significant neonatal complications (ie intraventricular hemorrhage, meningitis, hypoxic-ischemic encephalopathy) 5. Known complex Central Nervous System (CNS) malformation identified by neuroimaging

Study Design


Intervention

Other:
Assessments of Development and Growth
Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 5 years, 6 years, 7 years, 8 years, 9 years of age.

Locations

Country Name City State
United States Children's Hospital Colorado Aurora Colorado
United States Nemours at Thomas Jefferson University Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Longitudinal Descriptive Statistics of Cognitive Scores on the Bayley-III Cognitive skills will be assessed using the standardized Bayley Scales of Infant Development--3rd Edition (Bayley-3) 36 months
Primary Longitudinal Descriptive Statistics of Motor Scores on the Bayley-III Motor development will be assessed using the standardized Bayley Scales of Infant Development--3rd Edition (Bayley-3) 36 months
Primary Longitudinal Descriptive Statistics of Language Scores on Bayley-III Language development will be assessed using the Bayley Scales of Infant Development--3rd Edition (Bayley-3) 36 months
Secondary Body Mass Index (BMI) BMI will be determined through measurement of length and weight at the research visit. 36 months
Secondary Z Score The z score will be calculated for age group at the research visit. 36 months
Secondary Body Composition (% body fat) Body fat percentage will be measured using air Dual Energy X-Ray Absorptiometry (DEXA) at 3 year old visit. 3 year old visit
See also
  Status Clinical Trial Phase
Completed NCT02526628 - Thrombosis and Neurocognition in Klinefelter Syndrome
Completed NCT01678261 - X-chromosome Inactivation, Epigenetics and the Transcriptome N/A
Completed NCT01690013 - Life Quality and Health in Patients With Klinefelter Syndrome N/A
Completed NCT01918280 - Fertility Preservation in Cases of Klinefelter Syndrome. N/A
Completed NCT02787486 - Expanded Noninvasive Genomic Medical Assessment: The Enigma Study
Completed NCT03325647 - TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY Phase 4
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Recruiting NCT05498090 - Interrogating Fatty Acid Metabolism Impairment and Clinical Correlates in Males With Klinefelter Syndrome Phase 4
Completed NCT00999310 - Neuropsychologic, Neuroradiologic, Endocrinologic, and Genetic Aspects of Klinefelter Syndrome N/A
Completed NCT02408445 - Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment Phase 4
Completed NCT00896272 - Adaptation Among Adolescents and Adults With Klinefelter Syndrome
Completed NCT02723305 - Cardiometabolic Profiles of Boys With Klinefelter Syndrome
Completed NCT05581147 - Thyroid Function and Structure IN Klinefelter Syndrome
Recruiting NCT05586802 - Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome Phase 3
Active, not recruiting NCT02430584 - Whole Blood Specimen Collection From Pregnant Subjects
Completed NCT01817296 - Klinefelter Fertility Preservation N/A
Completed NCT01585831 - Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome N/A
Completed NCT01206270 - Androgen for Leydig Cell Proliferation Phase 2/Phase 3
Withdrawn NCT00347464 - Adaptive Behavior Assessment of Men With 49, XXXXY, Klinefelter Syndrome N/A
Recruiting NCT05425953 - Endocrine, Metabolic, Cardiovascular and Immunological Aspects of Sex Chromosome Abnormalities in Relation to Genotype